CBT-004, if approved, would be the first and only treatment for pinguecula, an ophthalmic condition impacting more than 50 million people in the U.S. alone In prior studies, CBT-004 demonstrated an ...
Please provide your email address to receive an email when new articles are posted on . CBT-004 demonstrated rapid onset of improvement in conjunctival hyperemia. Cloudbreak Pharma is advancing ...
The planned Phase 3 program will assess efficacy at three months and safety at twelve months, with primary endpoints including both a sign and symptom of pinguecula that showed statistical ...
Novel preservative-free CBT-004 eye drop formulation demonstrates statistically significant improvements in conjunctival hyperemia and patient-reported symptoms with excellent safety profile IRVINE, ...
In the completed Phase 2 study involving 88 patients with vascularized pinguecula, both tested concentrations of CBT-004 demonstrated statistically significant improvements in conjunctival hyperemia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results